HIGH-DOSE MELPHALAN WITH AUTOLOGOUS BONE-MARROW RESCUE FOR THE TREATMENT OF ADVANCED ADULT SOLID TUMORS
- 1 January 1984
- journal article
- research article
- Vol. 68 (3) , 471-474
Abstract
High-dose melphalan followed by rescue with autologous marrow stored for 12-24 h at room temperature was used in the treatment of 14 patients with advanced tumors refractory to conventional treatment. Twelve patients were evaluable, with 3 complete responses (25%), 5 partial responses (42%) and 2 minimal responses (16%). Response durations ranged from 4-38 wk (median, 7). There were 2 treatment-related deaths and 1 patient developed acute nonlymphocytic leukemia 3 mo. after a 2nd course of high-dose melphalan.This publication has 8 references indexed in Scilit:
- Autologous bone marrow rescue in the treatment of advanced tumors of childhoodCancer, 1982
- High-dose melphalan with autologous marrow for treatment of advanced neuroblastomaBritish Journal of Cancer, 1982
- HIGH-DOSE AMSA AND BONE-MARROW RESCUE IN PATIENTS WITH SOLID TUMORS1982
- PHASE-I STUDY OF HIGH-DOSE MITOMYCIN WITH AUTOLOGOUS BONE-MARROW SUPPORT1982
- High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumorsCancer, 1980
- Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalanBritish Journal of Cancer, 1979
- HIGH-DOSE BCNU THERAPY WITH AUTOLOGOUS BONE-MARROW INFUSION - PRELIMINARY-OBSERVATIONS1979
- Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant diseasePublished by Elsevier ,1978